Cargando…
Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.
In ovarian carcinoma cells, the combination of interferon-gamma (IFN-gamma) and cisplatin (cDDP) has been reported to result in a synergistic amplification of antiproliferative activity. To assess whether IFN-gamma may also prevent the occurrence of cisplatin resistance, the human ovarian carcinoma...
Autores principales: | Marth, C., Widschwendter, M., Kaern, J., Jørgensen, N. P., Windbichler, G., Zeimet, A. G., Tropé, C., Daxenbichler, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228156/ https://www.ncbi.nlm.nih.gov/pubmed/9374379 |
Ejemplares similares
-
High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.
por: Zeimet, A. G., et al.
Publicado: (1997) -
Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue
por: Doppler, W, et al.
Publicado: (2005) -
Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro
por: Widschwendter, M, et al.
Publicado: (1999) -
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
por: Windbichler, G H, et al.
Publicado: (2000) -
Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data
por: Steinkasserer, Lena, et al.
Publicado: (2021)